INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare has today announced the launch of Remsima™ (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, ...
INCHEON, South Korea — Celltrion, Inc. (KRX:068270) today announced that the company has completed Phase 3 clinical trial for ‘Remsima SC’, the subcutaneous (SC) version of Remsima®, the autoimmune ...
Celltrion announced on the 28th that the market share of its autoimmune disease treatment 'Remsima SC (ingredient name infliximab)' has more than quintupled in the European market within four years of ...
Celltrion said on the 11th that it has launched the liquid formulation of its autoimmune disease treatment Remsima (ingredient name Infliximab) in Europe. According to Celltrion, the company recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results